Novartis drug Afinitor gets EU nod for breast cancer






Novartis drug Afinitor gets EU nod for breast cancer



ZURICH (Reuters) - Novartis drug Afinitor, expected to become a major seller for the Swiss drugmaker, was approved by European regulators to treat women with a certain type of breast cancer, the company said on Monday. The drug is the first in a class known as mTOR inhibitors to be approved for post-menopausal women with advanced hormone-receptor positive, HER2-negative breast cancer. American health regulators also backed the drug as a breast cancer treatment. ...






Popular posts from this blog

Russian opposition leader charged with theft

Iran unveils long-range drone: state TV

The Censorship Game: Chinese Twitter Will Score User Behavior